| pubmed-article:20850972 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0226896 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0205531 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C1527415 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0068603 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0072780 | lld:lifeskim |
| pubmed-article:20850972 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:20850972 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:20850972 | pubmed:dateCreated | 2010-10-19 | lld:pubmed |
| pubmed-article:20850972 | pubmed:abstractText | The rational design of a novel series of pyrrolidine derivatives as neurokinin-3 receptor antagonists is reported starting from a selective neurokinin-1 receptor antagonist. Typical representatives in this series showed in vivo efficacy after oral administration in a NK3 mediated functional assay. This series of NK3 antagonists shows promise to deliver a novel antipsychotic. | lld:pubmed |
| pubmed-article:20850972 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20850972 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20850972 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20850972 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20850972 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20850972 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20850972 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20850972 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:20850972 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:HoffmannTorst... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:BallardTheres... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:SpoorenWillW | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:BissantzCater... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:KnustHennerH | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:NettekovenMat... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:RiemerClausC | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:RatniHassenH | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:JablonskiPhil... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:Patiny-AdamAn... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:SchmittMoniqu... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:KnoflachFrede... | lld:pubmed |
| pubmed-article:20850972 | pubmed:author | pubmed-author:MalherbeParic... | lld:pubmed |
| pubmed-article:20850972 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20850972 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20850972 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:20850972 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:20850972 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20850972 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20850972 | pubmed:pagination | 6735-8 | lld:pubmed |
| pubmed-article:20850972 | pubmed:meshHeading | pubmed-meshheading:20850972... | lld:pubmed |
| pubmed-article:20850972 | pubmed:meshHeading | pubmed-meshheading:20850972... | lld:pubmed |
| pubmed-article:20850972 | pubmed:meshHeading | pubmed-meshheading:20850972... | lld:pubmed |
| pubmed-article:20850972 | pubmed:meshHeading | pubmed-meshheading:20850972... | lld:pubmed |
| pubmed-article:20850972 | pubmed:meshHeading | pubmed-meshheading:20850972... | lld:pubmed |
| pubmed-article:20850972 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20850972 | pubmed:articleTitle | Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists. | lld:pubmed |
| pubmed-article:20850972 | pubmed:affiliation | F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, Preclinical Research, CH-4070 Basel, Switzerland. hasane.ratni@roche.com | lld:pubmed |
| pubmed-article:20850972 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20850972 | lld:chembl |
